麻豆传媒

Antonio Giordano, MD, PhD, is an oncologist and geneticist, as well as founder and president of the Sbarro Health Research Organization and director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University in Philadelphia, Pennsylvania. He works on molecular therapeutics and also studies the connections between obesity and cancer. Antonio Giordano grew up in Naples, Italy, where his father, Giovan Giacomo Giordano, was an oncologist and pathologist at the National Cancer Institute of Naples and a professor at the University of Naples. Giordano decided to branch out and start a career in research that was more oriented towards genetics applied to pathology. Early on, while following his father's research, he became interested in the link between the effect of toxic waste on the environment and the increasing cancer rates in the Campania region in Italy. Giordano earned his medical degree at the University of Naples in 1986, and his doctorate at the University of Trieste in 1990. He has published over 600 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. His early research includes seminal work done in 1989, demonstrating the importance of cell cycle proteins in the functioning of DNA tumor viruses. The transforming gene products of these viruses, such as the E1A oncoproteins of adenovirus 5, led to the identification of cellular factor p60, known as cyclin A. This research was the first demonstration of a physical link between cellular transformation and the cell cycle, thereby paving the way for the melding of these two areas of research. It also helped to open a very exciting avenue of research involving investigators with expertise in different aspects of growth control and cancer.Giordano’s lab also discovered the tumor suppressor gene RB2/p130 and the cell cycle kinases CDK9 and CDK10, two other key players in cell cycle regulation and cell differentiation. Antonio Giordano is the recipient of the Irving J. Selikoff Award for Cancer Research, the Rotary International Award, and Lions Club Napoli-Europa. He has also received the title of Knight of the Republic and Commander of the Order of Merit of the Italian Republic. At the 25th anniversary of the National Organization of Italian American Women, he was awarded the Cross of Merit Melitense, an honor of the Sovereign Military Order of Malta. www.shro.org www.drantoniogiordano.com

Sisson is an assistant professor at the Virginia Commonwealth University鈥檚 School of Pharmacy where he teaches pharmacy, nursing and medical students about drug therapy for hypertension, dyslipidemia and diabetes. 

Sandra currently works independently as a nutrition and diabetes educator consultant, as well as Director of Nutrition Services and Community Outreach at South Bronx Health Center, a program of Montefiore and The Children鈥檚 Health Fund. 

Kemmis is a physical therapist and certified diabetes educator at SUNY Upstate Medical University in Syracuse, New York, where she splits her time between the Joslin Diabetes Center affiliate and as an adjunct professor for the PT program. 

Antinori-Lent is a diabetes clinical nurse specialist at the University of Pittsburgh Medical Center - Shadyside Hospital, in Pittsburgh, Pennsylvania.

Spangler is one of the world's leading experts in tobacco epidemiology and was the keynote speaker for 2004 World Health Organization Tobacco and Community Health Conference in New Delhi, India. He founded the first physician-run tobacco-cessation clinic in North Carolina and was recently awarded $1.6 million grant to develop tobacco cessation curriculum for medical schools across the United States. He has won several prestigious awards including the Association of Teachers of Preventative Medicine Program of the Year Award and the Behavioral Sciences Forum Program of the Year Award. He is currently co-Principal Investigator on a longitudinal study of tobacco use among students at 11 colleges and universities in NC and VA.

Michelle Litchman, PhD, FNP-BC, FAANP, is an expert in diabetes care and using social media and other online resources to monitor how people with diabetes manage their own health in the real world. Litchman is an Assistant Professor at the College of Nursing and School of Medicine. Her position includes research, teaching, and clinical work at the Utah Diabetes and Endocrinology Center. She is passionate about teaching and precepts health sciences students and teaches didactic courses at the College of Nursing. Dr. Litchman’s program of research emphasizes the social context of chronic disease management across the lifespan with a particular emphasis on diabetes and technology. Her research examines online environments to understand the influence of peer support on health outcomes and diabetes management in the “real-world”. Dr. Litchman also examines family dynamics to understand how diabetes management is supported or derailed, and how technology might be helpful.

The research interests of Dr. Boerwinkle encompass the genetic analysis of the common chronic diseases in humans, including coronary artery disease, hypertension, and non-insulin-dependent (type II) diabetes.
Dr. Boerwinkle received his B.S. in Biology from the University of Cincinnati in 1980, an M.A. in Statistics (1984), and M.S. and Ph.D. in Human Genetics (1985) from the University of Michigan, Ann Arbor where he served as Senior Research Associate in the Department of Human Genetics from 1985-1986. He joined the University of Texas-Houston Center for Demographic/ Population Genetics in 1986 as a Research Assistant and became Assistant Professor in the same year. In 1991 he joined the Department of Human Genetics at the School of Public Health, University of Texas-Houston Health Science Center as Associate Professor, in 1996 was promoted to Professor, and in 1997, Director of the Human Genetics Center. He became a faculty member of the Institute of Molecular Medicine in 1996 and became Professor and Director of the Research Center for Human Genetics.

Dr. Boerwinkle is a member of the American Diabetes Association and the American Society of Human Genetics. The research interests of Dr. Boerwinkle encompass the genetic analysis of common chronic diseases in humans, including coronary artery disease, hypertension, and non-insulin-dependent (type II) diabetes. This work includes localizing genes which contribute to disease risk, identification of potentially functional mutations within these genes, testing these candidate functional mutations in experimental systems, defining the impact of gene variation on the epidemiology of the disease, and determining the extent to which these genes interact with environmental factors to contribute to disease risk. Activities include both statistical analysis and laboratory work. A large part of Dr. Boerwinkle's current research effort consists of localizing genes contributing to disease risk using modern genome-wide mapping methods. Success depends on keeping up with the latest genomic technical advances. The laboratory is set-up and operating as a high throughput sequencing and genotyping facility in which speed, accuracy and efficiency are monitored continuously. However, we are constantly seeking out more efficient methods to collect and manage genetic information.

Dr. Boerwinkle and colleagues have completed the world's first genome-wide analyses for a variety of CAD risk factors, including diabetes and hypertension. These investigations have to lead to the identification of novel susceptibility genes in both cases. Dr. Boerwinkle is particularly interested in methods for identifying potentially functional mutations within a gene region. This seemingly simple objective is made difficult because the functional mutations are expected to have small effects and are embedded in a sea of silent genetic variation. Once nearly all of the variation is cataloged directly by DNA sequencing, individuals are genotyped for each variable site. Both novel and traditional statistical methods are applied to relate the array of genetic information to a wealth of phenotypic data. This algorithm generates "candidate functional mutations" that are then tested in an in vitro or mouse model system. Once a functional mutation has been identified, Dr. Boerwinkle's group evaluates the ability of the variable site to predict the onset of disease (e.g. myocardial infarction or stroke) above and beyond traditional risk factors. This work is carried out as part of multiple prospective studies of cardiovascular disease and its risk factors in tens of thousands of individuals representing the major American ethnic groups.

Finally, he is working on experimental designs for studying genotype by environment interaction in humans. In particular, we are working on the extent to which inter-individual variation in lipid-lowering and antihypertensive medications are influenced by genetic factors. The practical objective of the research is to use genetic information to identify individuals at increase risk of disease and to design more efficacious interventions. Genetic studies are defining, at the molecular level, novel mechanisms of disease risk, onset and progression. Dr. Boerwinkle and collaborators address the localization of genes which contribute to disease risk in cardiovascular diseases, hypertension and diabetes. The methodology used involves screening of families having the disease and linking the presence of disease with known markers of the human genome. In this manner, the genomic region in which relevant mutations are located can be mapped and the relevant DNA sequenced. By assessing the structural change the mutation may have caused in the gene product (protein), it is possible to infer how it may affect biological function. In order to determine experimentally whether a mutation is functional, it is necessary to introduce the mutated gene into an animal, usually a mouse, and assess its biological effects on the animal's phenotype.

Dr. Boerwinkle has participated in multiple notable discoveries since joining the Institute. Only two will be highlighted here. First, Dr. Boerwinkle's group has completed the first-ever genome-wide search for genes contributing to inter-individual blood pressure levels. This initial effort has lead to the identification of an important gene (an adrenergic receptor) that influences blood pressure levels and the risk of hypertension. This is the first time that such a genome-wide approach has led to the identification of a susceptibility gene to a major cardiovascular disease risk factor. Second, Dr. Boerwinkle has participated in similar efforts to identify genes contributing to the risk of developing non-insulin-dependent (type II) diabetes. In this case, however, there were no genes in the region that were suspects for the disease. A team of collaborating investigators has painstakingly characterized the genetic region and identified the mutated gene (in this case a protease). This is the first time that anyone has ever positionally cloned a gene contributing to any common chronic disease. This work is of obvious potential clinical importance. It may lead to improved prediction of those at increased risk of disease and the design of more efficacious intervention strategies. The technologies and information from the human genome project provide new tools for lessening the burden of ill-health. Dr. Boerwinkle's accomplishments in developing an internationally recognized team of investigators targeting the genetics of cardiovascular disease and its risk factors ensure a productive future and further discoveries. 

Dr. Sharma is a trained dietitian and physical therapist. As a health professional, she strongly felt she was treating preventable diseases stemming from poor lifestyles: heart disease, diabetes, and hypertension. She saw the repercussions were devastating to the community. Her love for teaching, academics and the community-led her to pursue a Ph.D. in public health, focusing on epidemiology. Her interest is in nutrition and physical activity-based interventions to address obesity via school, family, and the community, predominantly in low-income minority populations. She co-founded Brighter Bites, a partner program of the Houston Food Bank, and serves on the Mayor of Houston’s Go Healthy Houston Task Force. She is currently working on Healthy Eating Active Living (HE/AL). Dr. Sharma explains, “HE/AL is designed to promote healthy birth outcomes and prevent maternally and childhood obesity among low-income Medicaid patients. The project will use evidence-based strategies from Brighter Bites, Legacy of Health, and The Happy Kitchen/La Cocina Alegre to promote breastfeeding and physical activity among pregnant women and women with infants. Families will receive free group education classes (nutrition, cooking, and exercise) and 30 lbs of fresh, seasonal fruits and vegetables weekly for 12 weeks. We will be tracking the effect of the program on maternal weight gain during pregnancy, gestational diabetes, pregnancy-induced hypertension, infant birth weight, breastfeeding, and infant weight gain in the first year of life.”

Dr. Gaber serves as Chair of Houston Methodist's Department of Surgery. He received his first academic appointment in 1987, as an Assistant Professor in the Department of Surgery at the University of Tennessee in Memphis. He became an Associate Professor there in 1991, and received his full professorship and was named to the Baptist Memorial Health Care Foundation chair of excellence in transplantation in 1994. While at the University of Tennessee, Dr. Gaber also held professorships in the Departments of Pharmacy and in the College of Nursing. He was also the Medical Director for the University of Tennessee Bowld Hospital, and the Methodist University Transplant Institute. Dr. Gaber is a prolific researcher and has authored over 300 scientific papers, as well as more than 340 abstracts and numerous book chapters, and his research has been funded by numerous grants from the National Institutes of Health, the Juvenile Diabetes Research Foundation, and several national and local foundations. Dr. Gaber assumed his positions at the Houston Methodist Hospital and Research Institute in Houston in 2006. While also conducting transplant immunotherapy research for liver and kidney whole organ transplants and allografts, the main focus of Dr. Gaber´s research is in the transplantation of islets to alleviate diabetic complications. He and his collaborators have developed the protocol for long term islet culture and described the clinical transplantation of islets through the intestinal veins. Dr. Gaber´s current studies center on the testing of gene therapy and other approaches to test for islet viability and assist the transplanted islets to develop a sustaining blood supply and resist rejection by the recipient's immune system.

Arti Thangudu, MD, is a triple board-certified physician and endocrinology, diabetes, and thyroid specialist who provides high-level, well-rounded care at Complete Medicine in San Antonio, Texas. She takes an evidence-based approach to care, focusing on the whole patient, not their disease or symptoms. At her membership-based practice, Dr. Thangudu offers her patients direct access, frequent coaching, and continuous blood glucose monitoring. After earning her Bachelor of Science in Journalism at Northwestern University in Evanston, Illinois, Dr. Thangudu received her Doctor of Medicine from the University of Texas Health Science Center in San Antonio. She completed a rigorous internship in internal medicine at Baylor College of Medicine, where she treated thousands of the sickest patients in public, private, and Veteran’s Administration hospitals and clinics throughout Houston, Texas. She then relocated to New Orleans, Louisiana, to complete her internal medicine residency at Tulane University. Dr. Thangudu moved to Pittsburgh, Pennsylvania, to complete her fellowship in endocrinology, diabetes, and metabolism at the University of Pittsburgh Medical Center, one of the busiest endocrinology training centers in the country. During her fellowship, she saw thousands of complex and rare cases in and out of the hospital and participated in research and quality improvement projects to improve care for people with diabetes. After her training, she moved on to work at one of the largest endocrinology groups in the country, where her passion grew and pushed her to pursue nutritional training at Cornell University’s Center for Nutrition Studies. Dr. Thangudu holds board certification in internal and lifestyle medicine, as well as endocrinology, diabetes, and metabolism. She’s also certified in plant-based nutrition.

The long-term goal of our research program is to elucidate mechanisms of obesity-associated coronary microvascular dysfunction and thereby identify novel pathways and therapeutic targets to reduce cardiovascular complications in these patients. The central premise of our work is that coronary microvascular dysfunction and the resultant impairment of coronary blood flow control is an independent predictor of cardiovascular morbidity and mortality in obese, diabetic patients. Impaired coronary microvascular function is estimated to account for more than 60% of cardiac perfusion defects in patients with type 2 diabetes. Thus, coronary microvascular dysfunction is a significant contributor to impaired cardiac function, ischemia, infarct, and mortality in these patients.

Current projects in the laboratory focus on the role of the aldosterone-binding mineralocorticoid receptor (MR) as a mediator of coronary and cardiac dysfunction in obesity. A growing body of evidence has implicated MR signaling in vascular cells as an important mediator of vascular and cardiac dysfunction in various disease states. Our studies utilize an integrative combination of in vivo and in vitro approaches including cell/tissue culture and clinically relevant mouse models coupled with molecular techniques.

The research in my lab is primarily concerned with understanding the effects of dietary genistein and other nutriceuticals (and exercise) on intestinal function.

Genistein is an isoflavonic phytoestrogen found naturally in soy, and a known activator of the CFTR chloride channel. Cystic fibrosis (CF) is an inherited disease in which epithelia are adversely affected by loss of proper CFTR function (i.e. sweat duct, pancreas, vas deferens, airway and intestine). \We have shown that consuming dietary genistein increases basal and cAMP-mediated chloride secretion in female wild-type (Wt) murine jejuna and in the well established DeltaF508-CF mouse dietary genistein eliminates the dependence of CF mice for laxatives.  Current work is aimed to evaluate how genistein mediates  benficial effect on survival and weight gain in CF mice.   We have shown that diabetic/obese ob/ob mice have significantly reduced jejunal basal chloride secretion, and furthermore, we demonstrate that consuming genistein-diet will rescue this deficit in basal secretion via influences on intestinal ion transporters.  Recent work in my lab is aimed to evaluate the influence of genistein and exercise in mice fed a high-fat/high-sugar (HFHS) diet, a model of diet-induced diabetic obesity, known to lead to Alzheimer's like pathology. In this model we are examining the gut brain axis.

Current studies in the lab are aimed at determining the mechanism(s) of action of genistein on intestinal function in Wt, CF, ob/ob and HFHS-fed mice, and importantly understanding the sex-dependent differences observed.

My research program is focused on the cell biology of recently deorphanized receptors and their cognate peptides as well as structural cues for cellular function. Specifically I am focused on these interactions at the interface of the retinal pigmented epithelium and underlying Bruch鈥檚 membrane of the eye. In addition, I direct the Research Microscopy and Histology Core at Saint Louis University School of Medicine.

Biography
Dr. Tessem received his Bachelors degree in Microbiology from Brigham Young University in 2001 and his Ph.D. in Biochemistry and Molecular Biology from the University of Colorado Health Sciences Center in 2007. Dr. Tessem completed a post-doctoral fellowship with Christopher Newgard at the Duke University Medical Center's Sarah W. Stedman Center for Nutrition and Metabolism Research.

Research Interests
Both Type 1 (T1D) and Type 2 diabetes (T2D) are caused by a relative insufficiency in functional 尾-cell mass. Current therapeutic options for diabetes include daily insulin injections to maintain normoglycemia, pharmacological agents to stimulate 尾-cell function and enhance insulin sensitivity, or islet transplantation. A major obstacle to greater application of islet transplantation therapy is the scarcity of human islets. Thus, new methods for expansion of 尾-cell mass, applied in vitro to generate the large numbers of human islet cells needed for transplantation, or in situ to induce expansion of the patients remaining 尾-cells, could have broad therapeutic implications for this disease. To this end, our lab is interested in delineating the molecular pathways that increase 尾-cell proliferation, enhance glucose stimulated insulin secretion, and protect against 尾-cell death.

Teaching Interests
My teaching interests focus on nutrient metabolism and biochemistry. I am interested in the metabolic disorders that cause human diseases.

A Boston-area resident, Anderson-Haynes is the founder and owner of a private practice specializing in holistic health and wellness for females. She鈥檚 certified in adult weight management, a certified personal trainer and a certified diabetes care and education specialist. She graduated from the University of Florida and Andrews University.

Dr. Sanjay Rajagopalan is the Chief of Cardiovascular Medicine for University Hospitals Harrington Heart & Vascular Institute, the Herman K. Hellerstein, MD Professor of Cardiovascular Research, and Director of the Case Cardiovascular Research Institute at Case Western Reserve University School of Medicine in Cleveland, Ohio.

Dr. Rajagopalan completed internal medicine training, including serving as Chief Resident, at SUNY (Buffalo, New York), Clinical and Research Fellowships in Cardiovascular Medicine/Vascular Biology at the Emory University School of Medicine (Atlanta, Georgia) and Cardiovascular Magnetic Resonance Imaging training at Duke University Medical Center (Durham, North Carolina).

Dr. Rajagopalan is among an elite group of physician scientists whose work has helped transform global perceptions of the impact of the environment on cardiovascular health. He is passionate about technology innovation in cardiovascular medicine for the development of personalized approaches to heart disease prevention.

Dr. Rajagopalan is an elected member of the American Society of Clinical Investigation (ASCI), American Association of Physicians (AAP), Association of University Cardiologists (AUC) and the Association of Professors of Cardiology (APC).

Director, Cardiovascular Research Institute, School of Medicine
Professor, Department of Medicine, School of Medicine

Research Interests
Dr. Rajagopalan completed clinical and research fellowships in cardiovascular medicine and vascular biology at the Emory University School of Medicine, Atlanta, Georgia. Dr. Rajagopalan is among an elite group of physician investigators whose work has help transform perceptions and facilitate understanding of the global impact of chronic diseases including diabetes. He has additionally made seminal contributions towards the development of next generation therapeutic modalities for the treatment of cardiovascular disease and is a leading authority in advancing newer and innovative non-invasive approaches for the diagnosis of complex cardiovascular disorders.

Dr. Rajagopalan鈥檚 laboratory has been continually funded by the National Institutes of Health (NIH). Dr. Rajagopalan is an elected member of the American Society of Clinical Investigation (ASCI), the Association of University Cardiologists (AUC) and the Association of Professors of Cardiology (APC). Additional honors include the William Keating Award from the American College of Cardiology, the Charles Dana Award and being voted amongst the Best Doctors in America.

Dr. Rajagopalan has published over than 250 original peer reviewed research publications in journals such as JAMA, New England Journal of Medicine, Circulation, Journal of Clinical Investigation and Circulation Research, in addition to more than 300 reviews, book chapters and abstracts. He has served as an editor for at least two textbooks and several monographs on vascular disease and atherosclerosis.

External Appointments
Division Chief, Cardiovascular Medicine University Hospitals Cleveland Medical Center
Publications
The NIEHS TaRGET II Consortium and environmental epigenomics. Wang T, Pehrsson EC, Purushotham D, Li D, Zhuo X, Zhang B, Lawson HA, Province MA, Krapp C, Lan Y, Coarfa C, Katz TA, Tang WY, Wang Z, Biswal S, Rajagopalan S, Colacino JA, Tsai ZT, Sartor MA, Neier K, Dolinoy DC, Pinto J, Hamanaka RB, Mutlu GM, Patisaul HB, Aylor DL, Crawford GE, Wiltshire T, Chadwick LH, Duncan CG, Garton AE, McAllister KA; TaRGET II Consortium, Bartolomei MS, Walker CL, Tyson FL. Nat Biotechnol. 2018 Mar 6;36(3):225-227. doi: 10.1038/nbt.4099.
Short-Term Blood Pressure Responses to Ambient Fine Particulate Matter Exposures at the Extremes of Global Air Pollution Concentrations. Huang W, Wang L, Li J, Liu M, Xu H, Liu S, Chen J, Zhang Y, Morishita M, Bard RL, Harkema JR, Rajagopalan S, Brook RD. Am J Hypertens. 2018 Feb 2. doi: 10.1093/ajh/hpx216. [Epub ahead of print] PMID: 29409056
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Brook RD, Rajagopalan S.J Am Soc Hypertens. 2018 Mar;12(3) PMID: 29396104
Exercise-Induced Pulmonary Hypertension: Translating Pathophysiological Concepts Into Clinical Practice. Naeije R, Saggar R, Badesch D, Rajagopalan S, Gargani L, Rischard F, Ferrara F, Marra AM, D' Alto M, Bull TM, Saggar R, Gr眉nig E, Bossone E.Chest. 2018 Jan 31. pii: S0012-3692(18)30161-2. doi: 10.1016/j.chest.2018.01.022. PMID: 29382472
CITED2 restrains pro-inflammatory macrophage activation and response. Kim GD, Das R, Rao X, Zhong J, Deiuliis JA, Ramirez-Bergeron DL, Rajagopalan S, Mahabeleshwar GH. Mol Cell Biol. 2017 Dec 4. pii: MCB.00452-17. doi: 10.1128/MCB.00452-17. PMID: 29203644
Noncoding RNAs in Cardiovascular Disease: Pathological Relevance and Emerging Role as Biomarkers and Therapeutics. Gangwar RS, Rajagopalan S, Natarajan R, Deiuliis JA. Am J Hypertens. 2018 Jan 12;31 PMID: 29186297
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. Rajagopalan S, Brook R. N Engl J Med. 2017 Nov 23;377(21):2098-9.No abstract available.  PMID: 29182250
Inhalation Exposure to PM2.5 Counteracts Hepatic Steatosis in Mice Fed High-fat Diet by Stimulating Hepatic Autophagy. Qiu Y, Zheng Z, Kim H, Yang Z, Zhang G, Shi X, Sun F, Peng C, Ding Y, Wang A, Chen LC, Rajagopalan S, Sun Q, Zhang K. Sci Rep. 2017 Nov 24;7(1):16286. doi: 10.1038/s41598-017-16490-3. PMID: 29176715 Free PMC Article
Monocyte DPP4 Expression in Human Atherosclerosis Is Associated With Obesity and Dyslipidemia. Rao X, Deiuliis JA, Mihai G, Varghese J, Xia C, Frieman MB, Sztalryd C, Sun XJ, Quon MJ, Taylor SI, Rajagopalan S, Zhong J.Diabetes Care. 2018 Jan;41(1)Epub 2017 Nov 10. PMID: 29127241
Effect of Particulate Matter Air Pollution on Cardiovascular Oxidative Stress Pathways. Rao X, Zhong J, Brook RD, Rajagopalan S. Antioxid Redox Signal. 2018 Mar 20;28(9):797-818. Epub 2017 Dec 12. PMID: 29084451
Extreme levels of ambient air pollution adversely impact cardiac and central aortic hemodynamics: the AIRCMD-China study. Liu S, Brook RD, Huang W, Fan Z, Xu H, Wu R, Sun Z, Zhao X, Ruan Y, Yan J, Sun L, Liang R, Lian H, Gu D, Rajagopalan S. J Am Soc Hypertens. 2017 Nov;11(11):754-761.e3. doi: 10.1016/j.jash.2017.09.009. Epub 2017 Sep 28. PMID: 29031802
The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature. Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. Am J Nephrol. 2017;46(4):298-314.  Epub 2017 Oct 10. PMID: 29017166
Personal-level exposure to environmental temperature is a superior predictor of endothelial-dependent vasodilatation than outdoor-ambient level. Ejike C, Wang L, Liu M, Wang W, Morishita M, Bard RL, Huang W, Harkema J, Rajagopalan S, Brook RD. J Am Soc Hypertens. 2017 Nov;11(11):746-753.e1.  Epub 2017 Sep 28. PMID: 28989070
Cardiovascular evaluation and management of iron overload cardiomyopathy in sickle cell disease. Ginwalla M, AlMasoud A, Tofovic D, Alin T, Al-Kindi S, Oliveira G, Rajagopalan S, Schilz R, Little J. Am J Hematol. 2018 Jan;93(1)Epub 2017 Oct 23.  PMID: 28971490
Design of the exercise MRI evaluation of HIV-pulmonary arterial hypertension longitudinal determinants (EXALTED) trial. Alaiti MA, Goud A, Ramani G, Bagchi S, Al-Kindi S, Sawicki S, Longenecker C, Jenkins T, Pauza D, Park M, McComsey G, Simonetti O, Hoit B, Rajagopalan S. J Cardiovasc Med (Hagerstown). 2017 Nov;18(11):888-896. PMID: 28937582
Stressed About Air Pollution: Time for Personal Action. Brook RD, Rajagopalan S. Circulation. 2017 Aug 15;136(7):628-631.   PMID: 28808145
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. Vora J, Ray K, Kosiborod M, Poulter NR, Rajagopalan S, Leiter LA. J Diabetes Complications. 2017 Sep;31(9):1451-1457. Epub 2017 Jun 15. Review. PMID: 28655490
Air Pollution and Cardiometabolic Disease: An Update and Call for Clinical Trials. Brook RD, Newby DE, Rajagopalan S. Am J Hypertens. 2017 Dec 8;31(1):1-10. doi: 10.1093/ajh/hpx109. PMID: 28655143
The regulatory role of DPP4 in atherosclerotic disease. Duan L, Rao X, Xia C, Rajagopalan S, Zhong J. Cardiovasc Diabetol. 2017 Jun 15;16(1):76. Review. PMID: 28619058 Free PMC Article
Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial. Rajagopalan S, Alaiti MA, Broadwater K, Goud A, Gaztanaga J, Connelly K, Fares A, Shirazian S, Kreatsoulas C, Farkouh M, Dobre M, Fink JC, Weir MR. Clin Cardiol. 2017 Sep;40(9) Epub 2017 May 26.
Education
Bachelor of Medicine and Bachelor of Surgery (MBBS) University of Madras, India 1988
Residencies, Internships and Fellowships
Residency in Internal Medicine Erie County Medical Center 1994
Fellowship in Cardiovascular Disease Emory University Hospital 1998
Research Fellowship in Cardiovascular Medicine Cornell University 2002
Fellowship in Cardiovascular Medicine Duke University Medical Center 2004
Additional Information
1990-1994: Assistant Instructor, Department of Internal Medicine, SUNY at Buffalo
1994: Chief Medical Resident, VA Medical Center, SUNY at Buffalo.
1994-1998: Instructor, Department of Internal Medicine, Emory University School of Medicine
1998-2003: Assistant Professor of Medicine, Division of Cardiology, University of Michigan, Ann Arbor
2001-2003:  Co-Director, Vascular Medicine Training Program, University of Michigan, Ann Arbor
2003-2006: Director Cardiovascular MR and CT Imaging, Mount Sinai School of Medicine, New York
2006-2013:Professor of Medicine (With Tenure), the Ohio State University, Columbus, Ohio
2006-2013: Director of Vascular Medicine, Co-Director CT and MR Imaging Program, The Ohio State University, Columbus, Ohio
2006-2013: Associate Director, Davis Heart Lung Research Institute, Columbus, OH
2013-2015:Head, Division of Cardiovascular Medicine, University of Maryland School of Medicine, Baltimore
2013-2016: Melvin Sharoky Endowed Professorship, University of Maryland School of Medicine
2016: Asst. Chair, Translational Research, Department of Medicine, University of Maryland School of Medicine

Karen Tabb Dina, PhD, MSW is professor in the University of Illinois Urbana-Champaign School of Social Work and faculty affiliate at Carle Foundation Hospital, the Lemann Institute for Brazilian Studies, and the Women and Gender in Global Perspectives. Her research agenda focuses identifying risk factors for morbidity and mortality among perinatal women and clinical factors to improve minority health. Dr. Tabb has authored over 80 publications, including articles in journals such as Ethnicity & Health, General Hospital Psychiatry, The Journal of Affective Disorders and the Journal of Psychosomatic Research. She is an expert collaborator (in the areas of diabetes, mental health, maternal health, and North America) for the Global Burden of Disease Study where she contributes in estimating population morbidity and mortality for 188 countries. She serves on the board of directors for the National Association of Perinatal Social Workers.
Dr. Tabb has received research and training support from several state and federal agencies including the Illinois DHS, the NIH and PCORI.  She has sustained a multi-site PCORI-funded project to engage pregnant and postpartum women as collaborators in perinatal depression research. Currently, she is Principal Investigator (PI) on an Illinois DHS project to improve outcomes in the first 1,000 days of life for 11 counties through systems development efforts.
Her research and commentary have appeared in numerous television, radio and print sources, including TEDx, WILL, WTAX, WCIA, WJBC, WRSP, WBBM, WTTW, InStyle Magazine, and the Washington Post Syndicate to name a few. In 2019, Dr. Tabb received the Robert Wood Johnson Foundation’s Thought Leader Award for Leading in Peer-Reviewed Publications, the New Connections Program’s premier honor for early career faculty. 
Karen Tabb Dina received her PhD in Social Welfare and a Certificate in Demographic Methods from the University of Washington in Seattle. She received her Master of Social Work, concentrating in Social Policy and Evaluation, from the University of Michigan in Ann Arbor and her Bachelor of Arts in Sociology from Eastern Michigan University.

Education

BA, Sociology, Eastern Michigan University, Ypsilanti
MSW, Social Policy & Evaluation, University of Michigan, Ann Arbor
PhD, Social Welfare and Social Demography, University of Washington, Seattle

Dr. Reece is the Assistant Dean for Student and Professional Affairs, Director of Interprofessional Education, and Associate Professor of Pharmacy Practice, all with the PCOM Georgia School of Pharmacy. She earned her Doctor of Pharmacy degree from Mercer University and completed a community pharmacy residency program with both Mercer University and The Kroger Company. Dr. Reece holds board certification in ambulatory care and advanced diabetes management. She served on the Board of Directors and as Treasurer of the Association of Diabetes Care and Education Specialists. She serves as Chair of the Endocrine and Metabolism PRN of the American College of Clinical Pharmacy and Chair of the Advocacy Committee for ADCES. She also serves as core faculty, ambulatory care pharmacist and diabetes specialist with Northeast Georgia Medical Center Family Medicine Graduate Medical Education Program.
Dr. Reece has a blog, Reece's Pieces in a Diabetes World, and a YouTube channel, ReecesPieces Diabetes. She presents on diabetes and technology related topics nationally.  Dr. Reece was named a 40 under 40 Pharmacist for the Georgia Pharmacy Association (2003), and presented with the Silver Shovel Award by the Greater Hall Chamber of Commerce (2011). She is a Fellow of the Association of Diabetes Care and Education Specialist (2017), an Outstanding Allied Health Professional by the Healthy Hall Greater Hall Chamber of Commerce (2019), a PCOM School of Pharmacy Teacher of the Year for Pharmacy Practice (2019), a PCOM School of Pharmacy Faculty Preceptor of the Year (2022 and 2023), and a Fellow of the American College of Clinical Pharmacy (2022).